Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma

scientific article

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.4049/JIMMUNOL.175.6.4137
P698PubMed publication ID16148164

P50authorHelen HeslopQ17386041
Karin StraathofQ91736091
Catherine M BollardQ91774704
Cliona M RooneyQ96221187
Ann M LeenQ98164176
Elizabeth L BuzaQ101573240
M Helen HulsQ109983498
P2093author name stringGraham Taylor
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectmembrane proteinQ423042
P304page(s)4137-4147
P577publication date2005-09-01
P1433published inJournal of ImmunologyQ3521441
P1476titleCharacterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma
P478volume175

Reverse relations

cites work (P2860)
Q47549907A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy
Q35222179Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer
Q57056125Adoptive cell therapy against EBV-related malignancies: a survey of clinical results
Q37008216Adoptive cellular immunotherapy for childhood malignancies
Q36513566Adoptive immunotherapy for Hodgkin's lymphoma
Q34242449Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma
Q40703339Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder.
Q45398515CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
Q27014912Cellular immunotherapy for pediatric solid tumors
Q37101134Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent
Q36059593Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
Q45029775Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals
Q37414729Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation
Q37117769Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma
Q37225034Emerging roles of small Epstein-Barr virus derived non-coding RNAs in epithelial malignancy
Q33578792Engineered T cells for cancer treatment
Q37129671Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
Q35238310Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector
Q42632595Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs.
Q90340855Generation of Norovirus-Specific T Cells From Human Donors With Extensive Cross-Reactivity to Variant Sequences: Implications for Immunotherapy
Q38759383Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant
Q33778708HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma
Q34166497HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China
Q35684896Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
Q43238571Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.
Q33303005Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy
Q45077858Immune evasion strategies of the human gamma-herpesviruses: implications for viral tumorigenesis
Q61797705Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation
Q38803361Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma
Q37268305Immunotherapy targeting EBV-expressing lymphoproliferative diseases
Q33634455Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Q59352682Novel ELISA for serodiagnosis of nasopharyngeal carcinoma based on a B cell epitope of Epstein-Barr virus latent membrane protein 2
Q28749468Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine
Q45045503Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses
Q33713932Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.
Q47728296Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients
Q59382383Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein-Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients
Q40185976Rescue of the immunotherapeutic potential of a novel T cell epitope in the Epstein-Barr virus latent membrane protein 2.
Q57176933Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target
Q45368108Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination
Q35068768Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins
Q36821993T cell therapies following hematopoietic stem cell transplantation: surely there must be a better way than DLI?
Q47114749The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors
Q34626576The molecular pathogenesis of Hodgkin lymphoma.
Q37995110The pathological roles of BART miRNAs in nasopharyngeal carcinoma
Q57056118Undifferentiated nasopharyngeal carcinoma from a nonendemic area: Protective role of HLA allele products presenting conserved EBV epitopes
Q53547204Use of CD107-based cell sorting ex vivo to enrich subdominant CD8+ T cells in culture.

Search more.